List of Excipients in Branded Drug OMEPRAZOLE, SODIUM BICARBONATE

Generic Drugs Containing OMEPRAZOLE, SODIUM BICARBONATE

Company	Ingredient	NDC	Excipient
Guardian Drug Company	omeprazole, sodium bicarbonate	53041-663	CROSCARMELLOSE SODIUM
Guardian Drug Company	omeprazole, sodium bicarbonate	53041-663	FD&C BLUE NO. 1
Guardian Drug Company	omeprazole, sodium bicarbonate	53041-663	FD&C BLUE NO. 2

What are the Most Frequently-Used Excipients in OMEPRAZOLE, SODIUM BICARBONATE?

# Of NDCs	Excipient
4	CROSCARMELLOSE SODIUM
3	FD&C BLUE NO. 1
4	FD&C BLUE NO. 2

Omeprazole Sodium Bicarbonate Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

Omeprazole/sodium bicarbonate is an immediate-release proton-pump inhibitor combination in which sodium bicarbonate is both an active antacid and a formulation-enabling excipient. The product avoids enteric coating by rapidly increasing gastric pH and protecting omeprazole from acid degradation. The commercial opportunity is concentrated in differentiated delivery formats, lower-sodium formulations, pediatric and institutional presentations, and manufacturing platforms that preserve rapid acid protection while reducing cost and complexity.

The reference product, Zegerid, is marketed in prescription capsules and powder-for-suspension formats. Core composition patents and regulatory exclusivities have largely expired, leaving formulation execution, regulatory strategy, supply reliability, and dosage-form differentiation as the principal competitive levers.

What is omeprazole sodium bicarbonate and how does the formulation work?

Omeprazole/sodium bicarbonate combines the acid-labile proton-pump inhibitor omeprazole with sodium bicarbonate. The combination is designed for immediate release rather than delayed release.

Sodium bicarbonate performs two functions:

1. It neutralizes gastric acid.
2. It creates a transient alkaline environment that protects omeprazole before absorption.

Conventional omeprazole products generally use enteric-coated granules, tablets, or capsules because omeprazole degrades rapidly in acidic conditions. Omeprazole/sodium bicarbonate products use a different design. The bicarbonate raises gastric pH quickly, allowing uncoated omeprazole to pass through the stomach with less acid exposure.[1]

The commercial implication is important: the product does not require the same enteric-coating system used by standard delayed-release proton-pump inhibitors. That can simplify manufacturing, but it transfers more formulation risk to bicarbonate loading, powder dispersion, moisture control, and dose uniformity.

What strengths and dosage forms are commercially available?

The principal prescription strengths are:

Dosage form	Omeprazole dose	Sodium bicarbonate dose	Primary formulation role
Capsule	20 mg	1,100 mg	Immediate-release oral capsule
Capsule	40 mg	1,100 mg	Higher-dose immediate-release capsule
Powder for oral suspension	20 mg	1,680 mg	Extemporaneous oral suspension
Powder for oral suspension	40 mg	1,680 mg	Higher-dose suspension

The sodium bicarbonate quantity is substantial. A 1,100 mg sodium bicarbonate dose contributes approximately 302 mg of elemental sodium. A 1,680 mg dose contributes approximately 460 mg of elemental sodium. That sodium burden creates a commercial constraint for patients requiring sodium restriction and creates an opportunity for alternative buffering strategies, although any substitute must preserve omeprazole stability and satisfy FDA combination-product requirements.

The powder-for-suspension presentation has a higher bicarbonate load than the capsule presentation. The difference reflects the formulation and administration requirements of the suspension product, including the need to maintain protection during preparation and oral delivery.[1][2]

What excipients are used in omeprazole sodium bicarbonate products?

The exact excipient profile varies by manufacturer and dosage form. Reference and generic products may use different combinations of fillers, binders, disintegrants, lubricants, glidants, suspending agents, sweeteners, and flavoring systems.

Common formulation functions include:

Excipient function	Examples of formulation needs
Bulking agent	Provides capsule or sachet mass and supports content uniformity
Binder	Maintains granule or powder integrity
Disintegrant	Promotes rapid dispersion after ingestion
Glidant	Improves powder flow and filling performance
Lubricant	Reduces manufacturing friction and sticking
Suspending agent	Maintains uniformity after reconstitution
Sweetener or flavor	Improves acceptability of oral suspension
Moisture-control agent	Limits degradation and caking
Alkaline buffer	Maintains the protective pH environment

Published product labels identify inactive ingredients that may include mannitol, crospovidone, povidone, hypromellose, magnesium stearate, sodium lauryl sulfate, sodium stearyl fumarate, colloidal silicon dioxide, talc, titanium dioxide, sucralose, and suspension-related excipients, depending on the presentation and manufacturer.[1][2]

For a generic applicant, matching the qualitative and quantitative excipient composition is not always necessary. The applicant must demonstrate pharmaceutical equivalence and bioequivalence, comply with inactive-ingredient requirements, and establish that the product performs adequately under the applicable FDA pathway. A formulation that materially changes wetting, dispersion, gastric neutralization, or omeprazole degradation may create bioequivalence and quality risks.

Which excipient attributes determine product performance?

Buffer capacity and acid-neutralization kinetics

The most important attribute is not simply the amount of sodium bicarbonate. It is the speed and durability of acid neutralization after administration.

A successful formulation must protect omeprazole during the relevant gastric residence period. Variables include:

• Particle size of sodium bicarbonate
• Surface area and dissolution rate
• Granule density
• Water activity
• Gastric-fluid interaction
• Dose volume
• Packaging moisture barrier

Fine bicarbonate may improve reaction speed but increase dusting, segregation, and moisture sensitivity. Coarser particles may improve handling but delay neutralization.

Omeprazole distribution and dose uniformity

Omeprazole is present at a much lower mass than sodium bicarbonate. The formulation therefore has a high active-to-buffer mass imbalance. Poor blending or segregation can produce low-dose or high-dose units even when the overall batch assay is acceptable.

Particle engineering, ordered mixing, granulation, and in-process blend testing are commercial priorities. A formulation with strong content uniformity can reduce batch rejection and improve manufacturing economics.

Moisture protection

Omeprazole is sensitive to degradation, and sodium bicarbonate can contribute to formulation instability through moisture uptake and chemical interaction. Packaging is therefore part of the formulation strategy.

Relevant options include:

• High-barrier blister packaging
• Desiccant-containing bottles
• Foil sachets
• Unit-dose packets
• Moisture-resistant capsule shells
• Low-moisture manufacturing environments

A lower-cost bottle may be commercially attractive but can create shelf-life and stability problems. Unit-dose packaging costs more but can improve institutional handling, adherence, and protection after dispensing.

Suspension behavior

For powder-for-suspension products, the formulation must disperse rapidly and remain adequately uniform during administration. A suspension that settles quickly can create dose variability. Critical characteristics include:

• Reconstitution volume
• Wetting time
• Ease of shaking
• Sedimentation rate
• Redispersibility
• Taste and mouthfeel
• Compatibility with oral syringes

Pediatric and hospital opportunities depend heavily on these attributes. A technically equivalent product with better reconstitution performance can compete without relying on a new active ingredient.

What formulation patents protect omeprazole sodium bicarbonate?

The historical patent estate focused on the combination of omeprazole with an alkaline agent, including sodium bicarbonate, and on immediate-release pharmaceutical compositions. Santarus, the original commercial sponsor associated with Zegerid, litigated patents covering omeprazole/bicarbonate products against generic applicants.

The principal historical litigation involved U.S. Patent Nos. 6,489,346 and 6,780,882. In Santarus, Inc. v. Par Pharmaceutical, Inc., the Federal Circuit addressed patent validity and infringement issues involving omeprazole and bicarbonate formulations.[3]

Patent or legal asset	Historical relevance	Current commercial significance
U.S. Patent No. 6,489,346	Omeprazole and bicarbonate composition technology	Core patent protection has expired
U.S. Patent No. 6,780,882	Related formulation and combination claims	Historical Paragraph IV barrier; expiration has passed
NDA 021636	Prescription Zegerid regulatory application	Supports reference-product substitution and generic review
Orange Book listings	Patent and exclusivity disclosure	Relevant to generic approval timing and certification strategy

The commercial value of the legacy estate was highest before generic entry. Current protection is more likely to arise from later patents directed to a specific powder matrix, suspension system, flavor system, capsule architecture, packaging configuration, or manufacturing process. Those rights can be commercially relevant only if they claim a meaningful performance advantage and survive obviousness, enablement, written-description, and non-infringement challenges.

What is the Orange Book status of omeprazole sodium bicarbonate?

Zegerid is an FDA-approved prescription product, and FDA Orange Book records historically identified the reference-listed drug and related patent information.[4] The original combination patents are no longer a durable barrier to generic entry.

A current applicant evaluating an abbreviated new drug application would typically assess:

• Whether the reference product has active listed patents
• Whether the applicant must file Paragraph IV certifications
• Whether any pediatric or other regulatory exclusivity remains
• Whether the proposed dosage form is therapeutically equivalent to the reference product
• Whether the applicant can rely on an existing reference product or requires a different regulatory pathway

No biosimilar pathway applies. Omeprazole is a small-molecule drug, so competition proceeds through the ANDA framework or, for materially different products, an NDA route such as a 505(b)(2) application.

When does omeprazole sodium bicarbonate lose exclusivity?

The active ingredient omeprazole has been generic for many years. The product-specific combination patents associated with Zegerid have also expired. FDA regulatory exclusivity associated with the original approval is no longer a meaningful commercial barrier.

The remaining exclusivity question is product-specific rather than molecule-specific. A later applicant could obtain limited protection for:

• A new dosage form
• A pediatric formulation
• A distinct suspension vehicle
• A novel taste-masking system
• A lower-sodium buffering approach
• A new indication supported by clinical data
• A manufacturing process that meets patentability requirements

Such protection would not restore exclusivity to conventional omeprazole/sodium bicarbonate capsules. It would apply only to the claimed product or use.

Which companies are challenging or competing with Zegerid?

Competition comes from three groups.

Generic omeprazole/sodium bicarbonate manufacturers

Generic manufacturers compete on:

• Wholesale acquisition cost
• Contract manufacturing reliability
• Authorized-distributor access
• Bottle and blister configuration
• Product availability
• Reimbursement and substitution status

The principal competitive risk to a new entrant is not patent litigation. It is price compression and limited market size.

Conventional omeprazole products

Delayed-release omeprazole capsules and tablets are the closest substitutes. They generally have broader physician familiarity, extensive generic availability, and lower formulation complexity.

Immediate-release omeprazole/sodium bicarbonate can differentiate through:

• Rapid onset positioning
• No enteric coating
• Capsule or suspension flexibility
• Alternative administration for selected patients
• Potential use where delayed-release products are difficult to administer

Other proton-pump inhibitors

Lansoprazole, pantoprazole, rabeprazole, and esomeprazole compete within the same therapeutic class. Most have generic versions and established hospital or retail channels. A commercial strategy based only on proton-pump inhibition is unlikely to be sufficient. The product must offer a delivery, handling, onset, sodium, taste, or supply-chain advantage.

What commercial opportunities exist for new excipient platforms?

Lower-sodium immediate-release formulations

The clearest formulation opportunity is reducing sodium exposure while preserving the protective function of bicarbonate or another alkaline system. A lower-sodium product could target patients for whom the reference sodium load is undesirable.

The challenge is that sodium bicarbonate is not an incidental excipient. It is central to the approved formulation mechanism. Replacing or reducing it may require a new clinical and regulatory package, especially if the proposed buffer changes absorption or exposure.

Pediatric and geriatric suspension products

A stable, palatable, ready-to-use or easy-to-reconstitute suspension could compete in patients who cannot swallow capsules. Commercial advantages may include:

• Unit-dose oral syringes
• Preservative-minimized formulations
• Improved taste masking
• Lower sedimentation
• Smaller administration volume
• Longer in-use stability after reconstitution

A pediatric product would require an appropriate dosing rationale and may qualify for pediatric development incentives only if the statutory requirements are met.

Unit-dose hospital and institutional packaging

Hospitals and long-term-care facilities value dose accuracy, fast preparation, and reduced medication waste. Sachets or premeasured suspension packets can improve workflow compared with bulk bottles.

The main barriers are packaging cost, procurement contracts, and the need to demonstrate stability across storage and administration conditions.

Orally disintegrating or sprinkle formats

A modified capsule, sprinkle product, or orally disintegrating format could address swallowing difficulties. The product must preserve the immediate-release bicarbonate mechanism and prevent acid exposure to omeprazole before it reaches the absorption site.

Sprinkle products also raise practical questions about:

• Food compatibility
• Tube administration
• Dose recovery from the vehicle
• Uniform distribution
• Palatability
• Stability after opening

Private-label and regional licensing

Because the active ingredients are mature, licensing value is likely to sit in the formulation platform, regulatory dossier, manufacturing capacity, or commercial channel rather than in the molecule itself.

Potential transaction structures include:

Structure	Strategic use
Contract manufacturing	Low-capital launch with outsourced production
Regional licensing	Local commercialization of an approved or differentiated dosage form
Private-label supply	Retail or institutional channel access
505(b)(2) partnership	Development of a differentiated dosage form
Formulation patent license	Access to proprietary suspension, buffering, or packaging technology

How strong is the patent estate for a new formulation?

A new formulation patent estate is strongest when it claims a measurable technical result that is difficult to design around. Examples include:

• A defined bicarbonate particle-size distribution
• A specific moisture threshold with demonstrated shelf-life benefit
• A suspension system with superior redispersibility
• A low-sodium buffer composition with equivalent exposure
• A capsule architecture that improves stability
• A manufacturing process that produces a required impurity profile

Weak claims typically cover the broad concept of combining omeprazole with an alkaline agent because that concept has substantial prior-art exposure. Stronger claims should be supported by comparative data showing unexpected stability, improved bioavailability, lower variability, or meaningful usability benefits.

Patent term should be planned from the earliest nonprovisional filing. A formulation patent filed after commercial launch may have a shorter remaining term and can be vulnerable to obviousness arguments if the formulation represents routine substitution of known excipients.

What generic launch risks exist?

The principal launch risks are commercial and technical:

1. Price erosion from multiple ANDA-approved products.
2. Limited market size relative to conventional omeprazole.
3. Sodium-related labeling and prescribing constraints.
4. Stability failures caused by moisture exposure.
5. Blend segregation from the low omeprazole load.
6. Suspension nonuniformity after reconstitution.
7. Difficulty demonstrating therapeutic equivalence for a differentiated dosage form.
8. Limited reimbursement preference for a premium product.
9. Manufacturing dependence on high-barrier packaging.
10. Substitution by standard delayed-release omeprazole.

A conventional generic capsule is likely to face the fastest price competition. A differentiated suspension, low-sodium product, or institutional unit-dose format can support better margins if it has a clear procurement or administration advantage.

What FDA regulatory pathway applies?

A conventional generic matching an approved omeprazole/sodium bicarbonate dosage form would generally pursue an ANDA and demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements.[5]

A product with a materially different dosage form, inactive-ingredient system, buffering strategy, administration method, or clinical use may require a 505(b)(2) NDA. That pathway can support innovation but carries greater development cost and may require additional clinical or pharmacokinetic evidence.

FDA review will focus on:

• Active ingredient identity and strength
• Immediate-release performance
• Impurity and degradation profile
• Content uniformity
• Stability
• Inactive-ingredient suitability
• Microbial quality for suspensions
• Labeling
• Container-closure performance
• Bioequivalence or clinical bridging

Key Takeaways

• Sodium bicarbonate is a functional component that protects omeprazole from gastric acid and enables immediate release.
• The principal commercial products are 20 mg and 40 mg capsules with 1,100 mg sodium bicarbonate and powder-for-suspension products with 1,680 mg.
• Moisture protection, blend uniformity, bicarbonate dissolution, and suspension redispersibility are the core formulation-control issues.
• The historical Zegerid combination patent estate has expired, and current competition is driven primarily by generic pricing and product execution.
• The most credible innovation opportunities are lower-sodium formulations, pediatric and geriatric suspensions, unit-dose institutional packaging, and differentiated administration formats.
• A broad combination patent is difficult to defend. Commercially useful patents should claim specific excipient systems, process controls, packaging designs, or demonstrated performance advantages.
• Conventional generic capsules face high price pressure. Specialty suspensions and institutional formats offer better opportunities for differentiation.

FAQs About Omeprazole Sodium Bicarbonate Excipient and Patent Strategy

Can sodium bicarbonate be removed from an omeprazole formulation?

Yes, but removing it changes the product’s protection mechanism and may require a different formulation and regulatory strategy. A conventional delayed-release omeprazole design would generally be a different product rather than a direct omeprazole/sodium bicarbonate equivalent.

Is omeprazole sodium bicarbonate eligible for biosimilar competition?

No. Omeprazole is a small-molecule drug. Competition is generally pursued through generic ANDA approval or, for differentiated products, an NDA pathway such as 505(b)(2).

Does Zegerid require an enteric coating?

The immediate-release omeprazole/sodium bicarbonate product is designed to avoid conventional enteric coating by using sodium bicarbonate to create an alkaline environment.

What is the main commercial weakness of omeprazole sodium bicarbonate?

The principal weakness is the sodium burden combined with competition from inexpensive delayed-release omeprazole products. The reference product also requires careful moisture and content-uniformity control.

Which formulation has the strongest commercial potential?

A stable, palatable, lower-sodium suspension or unit-dose product has the strongest differentiation potential. A standard capsule can enter more quickly but is likely to face substantial generic price competition.

References

1. U.S. Food and Drug Administration. (2023). Zegerid: Omeprazole and sodium bicarbonate prescribing information.
2. National Library of Medicine. (2024). DailyMed: Omeprazole and sodium bicarbonate capsule and powder for suspension labeling.
3. Santarus, Inc. v. Par Pharmaceutical, Inc., 694 F.3d 1344 (Fed. Cir. 2012).
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2024). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA.